Indications |
Oral Breast cancer Adult: 20 mg daily as a single dose or in 2 divided doses. Max: 40 mg/day. Oral Reduction of breast cancer incidence in women at high risk Adult: 20 mg daily for 5 yr. Oral Anovulatory infertility Adult: 20 mg daily on days 2-5 of the menstrual cycle. Max: 80 mg/day. |
Contraindications |
Pregnancy and lactation. History of thromboembolic events. |
Warnings / Precautions |
Perform routine haematological and liver function tests in long-term therapy. Gynaecological monitoring is necessary in women. |
Adverse Reactions |
Hot flushes, oedema, fluid retention, dry skin, vaginal bleeding, vaginal discharge, pruritus vulvae, GI upsets, nausea, dizziness, rashes, blurred vision, loss of acuity, alopecia, increased liver enzymes, hypertriglyceridaemia, uterine fibroids and endometrial hyperplasia. Potentially Fatal: Blood dyscrasias, cholestasis, hepatitis, hypercalcaemia in patients with bone metastasis, thromboembolic events. Increased risk of endometrial cancer and uterine sarcoma. |
Drug Interactions |
Aminoglutethimide reduces plasma-tamoxifen concentration. Potentially Fatal: Concurrent use increased anticoagulant effect of warfarin; increased risk of thromboembolic events with other cytotoxic drugs. See Below for More tamoxifen Drug Interactions |
Lab Interactions |
False increase of serum thyroxine concentration. False negative estrogen receptor determinations if performed within 4-6 wk after discontinuation of drug. |
Mechanism of Actions |
Tamoxifen, a triphenylethylene derivative, produces a nuclear complex by competitively binding to oestrogen receptors on tumours and other tissue targets thus, decreasing DNA synthesis and inhibiting oestrogen effect. It is only cytostatic rather than cytotoxic due to accumulation of cell in G0 and G1 phases. Absorption: Well absorbed from the GIT; peak plasma concentrations after 4-7 hr (oral). Distribution: Distributed into uterus (high concentrations), endometrial and breast tissues. Protein-binding: Extensive. Metabolism: Extensively metabolised in liver by the cytochrome P450 isoenzymes CYP3A4, CYP2C9, and CYP2D6, converted to desmethyltamoxifen; undergoes enterohepatic recycling. Excretion: Faeces (as conjugates), urine (small amounts); 7 days (terminal half-life). |
Storage Conditions |
Oral: Store between 20-25°C. |
Storage |
Oral: Store between 20-25°C. |
Available As |
|
Tamoxifen
Post Review about Tamoxifen Click here to cancel reply.
Tamoxifen Containing Brands
Tamoxifen is used in following diseases
Drug - Drug Interactions of Tamoxifen
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.